Serica

Seres Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, January 4, 2023
Science, Stem Cells, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Conference, PST, Therapy, EST, Pharmaceutical industry, Phonograph record, Serica

Seres Therapeutics, Inc .

Key Points: 
  • Seres Therapeutics, Inc .
  • (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 8:15 a.m. PST / 11:15 a.m. EST.
  • An audio webcast of the presentation will be available under the “Investors and News” section of Seres’ website.
  • A replay of the presentation will become available approximately one hour after the event and will be archived for approximately 21 days.

Global NEV Sales Reached 2.87 Million Units for 3Q22 as BYD Trailed Closely Behind Tesla in BEV Segment, Says TrendForce

Retrieved on: 
Thursday, November 24, 2022
EV, Electric Vehicles, Mobile, Wireless, Other Energy, Oil, Gas, Consumer Electronics, Alternative Vehicles, Fuels, Energy, General Automotive, Technology, Automotive, Semiconductor, Telecommunications, NEVS, Semiconductor Research Corporation, Volkswagen, Geometry, SAIC Motor, MG Motor, News, XPeng, Tesla, NEV, Autumn, BEV, Kia, Research, Quarter, BMW, Vacuum breaker, Serica, Mercedes-Benz, Blog, Yoy, Growth, BYD, SGMW, PHEV, Hyundai, Bev, SAIC, Motor vehicle, Retail, Huawei, Chinese

Of the quarterly total, BEV sales accounted for 2.147 million units and registered a YoY growth of 75%, whereas PHEV sales accounted for 714,000 units and registered a YoY growth of 57%.

Key Points: 
  • Of the quarterly total, BEV sales accounted for 2.147 million units and registered a YoY growth of 75%, whereas PHEV sales accounted for 714,000 units and registered a YoY growth of 57%.
  • In the global ranking of BEV brands by vehicle sales for 3Q22, Tesla took first place with 344,000 units.
  • While Tesla managed to maintain its market share at 16%, its lead over second-placed BYD in sales figure had narrowed further.
  • It is also worth noting that the gap between Tesla and BYD in BEV sales has been smaller than 100,000 units for two quarters straight.

Seres Therapeutics to Host Investor Webcast on December 8, 2022 to Discuss SER-109 Commercial Strategy

Retrieved on: 
Tuesday, November 22, 2022
FDA, Health, Infectious Diseases, Clinical Trials, Research, Science, FDA, Priority review, Clostridioides difficile infection, Ulcerative colitis, Therapy, NEJM, Spore, Medicine, Patient, The New England Journal of Medicine, Research, Recurrence, Hematopoietic stem cell transplantation, PDUFA, ID, Tissue, Variometer, David Berry (inventor), Bloodstream infections, Firmicutes, Graft-versus-host disease, Weill Cornell Medicine, Pharmaceutical industry, Serica

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will host an investor webcast to discuss the planned commercialization approach and market opportunity for therapeutic candidate SER-109 in recurrent C. difficile infection (rCDI) on Thursday, December 8, 2022, at 8:30 a.m.

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will host an investor webcast to discuss the planned commercialization approach and market opportunity for therapeutic candidate SER-109 in recurrent C. difficile infection (rCDI) on Thursday, December 8, 2022, at 8:30 a.m.
  • The SER-109 investor webcast will include members of management from Seres Therapeutics, Aimmune Therapeutics, Inc., a Nestl Health Science Company, as well as Carl Crawford M.D.
  • To join the live webcast, please visit the Investors and News section of the Seres website at www.serestherapeutics.com .
  • Seres Therapeutics, Inc. (Nasdaq: MCRB) is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease.

Cara Therapeutics Announces Appointment of Lisa von Moltke, M.D., to its Board of Directors

Retrieved on: 
Thursday, November 3, 2022
Company, Journal, Private Securities Litigation Reform Act, American College, Primary biliary cholangitis, Board, The Journal of Clinical Pharmacology, Serica, GLOBE, American College of Clinical Pharmacology, Atopic dermatitis, Chronic kidney disease, FDA, Translational medicine, Medicine, Senior, Itch, CEP, Therapy, Nasdaq, Michigan State University, Form 10-Q, Alkermes, Pharmacology, U.S. Securities and Exchange Commission, David Berry (inventor), Wellesley College, Board of directors, Notalgia paresthetica, Security (finance), Michigan State University College of Human Medicine, Patient, Pharmaceutical industry

STAMFORD, Conn., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc.(Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Lisa von Moltke, M.D., to its Board of Directors.

Key Points: 
  • STAMFORD, Conn., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc.(Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Lisa von Moltke, M.D., to its Board of Directors.
  • Dr. von Moltke currently serves as Executive Vice President and Chief Medical Officer at Seres Therapeutics, Inc.
    We are very pleased to welcome Lisa to our board of directors, said Christopher Posner, President, Chief Executive Officer and Director of Cara Therapeutics.
  • Its an exciting time to be joining the board of Cara Therapeutics, said Dr. von Moltke.
  • Dr. von Moltke has directed successful development programs, led clinical teams, and interacted with regulatory agencies across multiple therapeutic areas.

Seres Therapeutics to Host Third Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on November 2, 2022

Retrieved on: 
Thursday, October 27, 2022
Infectious Diseases, FDA, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Tissue, Hematopoietic stem cell transplantation, Ulcerative colitis, FDA, Therapy, Patient, Company, Nasdaq, Research, Bloodstream infections, David Berry (inventor), Graft-versus-host disease, Pharmaceutical industry, Serica

(Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on November 2, 2022, at 8:30 a.m.

Key Points: 
  • (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on November 2, 2022, at 8:30 a.m.
  • ET to discuss third quarter 2022 results and provide a general business update.
  • To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference conference ID 8315051.
  • To join the live webcast, please visit the Investors and News section of the Seres website at www.serestherapeutics.com .

Seres Therapeutics Announces FDA Acceptance of Biologics License Application for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection for Priority Review

Retrieved on: 
Wednesday, October 26, 2022
FDA, Health, Science, Research, Clinical Trials, U.S. Securities and Exchange Commission, CDC, PDUFA, Therapy, Risk, SEC, Growth, Review, Bloodstream infections, The New England Journal of Medicine, Variometer, Breakthrough therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, CDI, Patient, Prescription Drug User Fee Act, Research, Tissue, Advisory Committee, Security (finance), Hospital-acquired infection, Nasdaq, Orphan drug, Private Securities Litigation Reform Act, Food, Center, Company, Firmicutes, Perseverance, Graft-versus-host disease, David Berry (inventor), Spore, BLA, Adult, Hematopoietic stem cell transplantation, Recurrence, Korea Disease Control and Prevention Agency, Ulcerative colitis, Priority review, FDA, COVID-19, Biologics license application, Pharmaceutical industry, Serica

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for investigational oral microbiome therapeutic SER-109 for the prevention of recurrent C. difficile infection (rCDI).

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for investigational oral microbiome therapeutic SER-109 for the prevention of recurrent C. difficile infection (rCDI).
  • The application has been granted Priority Review designation with a Prescription Drug User Fee Act (PDUFA) action date of April 26, 2023.
  • The FDA advised that they are not currently planning to hold an Advisory Committee Meeting to discuss the SER-109 application.
  • Seres has received an upfront license payment of $175 million and will receive an additional $125 million upon FDA approval of SER-109.

Seres Therapeutics’ ECOSPOR III Study Data on SER-109 Published in Journal of the American Medical Association

Retrieved on: 
Wednesday, October 19, 2022
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Infectious Diseases, Clinical Trials, JAMA, U.S. Securities and Exchange Commission, Therapy, Risk, SEC, Growth, Bloodstream infections, The New England Journal of Medicine, Variometer, Breakthrough therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, CDI, Patient, Standard of care, Research, Tissue, Clostridioides difficile infection, Security (finance), Hospital-acquired infection, GI, Nasdaq, Orphan drug, History, Private Securities Litigation Reform Act, Food, Center, Company, Firmicutes, Graft-versus-host disease, David Berry (inventor), Spore, BLA, American Medical Association, Hematopoietic stem cell transplantation, Recurrence, Journal, Korea Disease Control and Prevention Agency, Ulcerative colitis, FDA, COVID-19, Biologics license application, Pharmaceutical industry, Serica

We are honored to see these important findings published in such a well-regarded medical research journal, said Lisa von Moltke, M.D., Chief Medical Officer at Seres and publication co-author.

Key Points: 
  • We are honored to see these important findings published in such a well-regarded medical research journal, said Lisa von Moltke, M.D., Chief Medical Officer at Seres and publication co-author.
  • The JAMA paper summarizes data from the secondary endpoints of the multicenter, double-blind ECOSPOR III trial ( NCT03183128 ), which enrolled 182 participants with a history of rCDI and randomly assigned them to receive either SER-109 or placebo.
  • While comorbidities were common among study participants in both arms of the study, SER-109 was well-tolerated with no serious treatment-related adverse events observed over the course of the 24-week study period.
  • These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Seres Therapeutics to Present Clinical Results at IDWeek and American College of Gastroenterology (ACG) 2022 Annual Meeting

Retrieved on: 
Wednesday, October 12, 2022
Health, FDA, Infectious Diseases, Clinical Trials, Research, Science, U.S. Securities and Exchange Commission, CDC, Infection, MBBS, Therapy, Risk, SEC, Growth, American College of Gastroenterology, Bloodstream infections, Variometer, Breakthrough therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Biologics license application, CDI, Patient, Gastroenterology, Research, Tissue, Clostridioides difficile infection, Security (finance), FACG, Nasdaq, Orphan drug, Private Securities Litigation Reform Act, Food, Company, Firmicutes, Industry, Graft-versus-host disease, ACG, David Berry (inventor), Spore, BLA, IBD, Hematopoietic stem cell transplantation, Ulcerative colitis, American College, FDA, Annual general meeting, COVID-19, Pharmaceutical industry, Serica, MD

SER-109 is an entirely new treatment modality that shows promise to improve the current standard of care for rCDI.

Key Points: 
  • SER-109 is an entirely new treatment modality that shows promise to improve the current standard of care for rCDI.
  • SER-109 is an oral microbiome therapeutic candidate consisting of a consortium of highly purified Firmicutes spores, which normally live in a healthy microbiome.
  • Seres SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA.
  • These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Seres Therapeutics to Present at World Anti-Microbial Resistance Congress

Retrieved on: 
Thursday, September 8, 2022
Health, FDA, Infectious Diseases, Stem Cells, Clinical Trials, Pharmaceutical, Biotechnology, Patient, COVID-19, Security (finance), BLA, Cancer, Cirrhosis, Hematopoietic stem cell transplantation, Research, Therapy, Food and Drug Administration, Infection, Tissue, Antimicrobial, National Harbor, Maryland, SEC, AMR, David Berry (inventor), Bloodstream infections, U.S. Securities and Exchange Commission, Carbapenem-resistant enterobacteriaceae, Nasdaq, Company, FDA, CRE, Clostridioides difficile infection, Immunodeficiency, Risk, Private Securities Litigation Reform Act, Ulcerative colitis, Growth, VRE, Graft-versus-host disease, Pharmaceutical industry, Serica

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Matthew Henn, Ph.D., Chief Scientific Officer at Seres, will be presenting at the World Anti-Microbial Resistance Congress being held on September 7-8, 2022 in National Harbor, Maryland.

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Matthew Henn, Ph.D., Chief Scientific Officer at Seres, will be presenting at the World Anti-Microbial Resistance Congress being held on September 7-8, 2022 in National Harbor, Maryland.
  • ET today a presentation entitled: Microbiome Therapeutics to Potentially Transform the Management of Antimicrobial Resistant Infections.
  • Seres clinical and preclinical data suggest that microbiome therapeutics may provide a novel approach to reduce the risk of antibiotic-resistant bacterial infection.
  • Seres approach developing microbiome therapeutics for Infection Protection has been clinically validated by the Companys SER-109 program, an investigational product for the prevention of recurrent C. difficile infection.

Seres Therapeutics Announces Completion of Rolling BLA Submission to FDA for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection

Retrieved on: 
Wednesday, September 7, 2022
FDA, Health, Research, Pharmaceutical, Science, Biotechnology, Patient, COVID-19, Security (finance), BLA, Hematopoietic stem cell transplantation, Research, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, Recurrence, Tissue, Spore, CDI, Variometer, Food, SEC, David Berry (inventor), Bloodstream infections, Infection, U.S. Securities and Exchange Commission, Leadership, Nasdaq, Breakthrough therapy, FDA, Company, Orphan drug, The New England Journal of Medicine, Risk, Private Securities Litigation Reform Act, Growth, Firmicutes, Ulcerative colitis, Review, Graft-versus-host disease, Pharmaceutical industry, MD, Serica

SER-109 has FDA Breakthrough Therapy designation, which provides the potential for priority review of the BLA.

Key Points: 
  • SER-109 has FDA Breakthrough Therapy designation, which provides the potential for priority review of the BLA.
  • If granted, Seres anticipates the potential approval and launch of SER-109 in the first half of 2023, with SER-109 potentially becoming the first ever FDA-approved oral microbiome therapeutic.
  • After well over a decade of research, Seres has established strong leadership in the development of microbiome therapeutics with a promising pipeline, said Eric Shaff, President and Chief Executive Officer at Seres.
  • The SER-109 program is being advanced to prevent further recurrences of C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic.